The Joint Corp. (NASDAQ: JYNT) is a Healthcare company (Medical - Care Facilities) with a market capitalization of $91M. The Maz Rating grades it against the other companies in its sector.
The Joint Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.65, The Joint Corp. trades at 33.5x trailing earnings, 1.6x sales and 7.7x book value, with an EV/EBITDA of 15.6. Over the last twelve months it generated about $58M of revenue and $3M of net income. It runs a gross margin of 81.6%, an operating margin of 4.4% and a net margin of 4.8%. It shows return on equity of 19.3%, return on invested capital of 10.6% and a free cash flow yield of 2.5%. On the balance sheet: a debt-to-equity ratio of 0.16 and a current ratio of 1.96. Over the past 52 weeks the share price ranged from $6.52 to $10.67, with a beta of 1.16.
The Joint Corp. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 4 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, The Joint Corp. (JYNT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.32% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.8% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.32% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.8% / 33% · Receivables / Mkt Cap (36m) 2.37% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.32% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.8% / 33.33% · Receivables / Mkt Cap (24m) 2.37% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.30% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 40.5% / 33.33% · Receivables / Avg Assets (4Q) 4.82% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.86% / 33.33% · (Cash+ST Inv) / Total Assets 45.0% / 33.33% · (Cash+Recv) / Total Assets 51.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, The Joint Corp. (JYNT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. The Joint Corp. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
The Joint Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.